Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancerdoi:10.1016/j.clbc.2016.06.004HER-2 positiveLapatinibNeoadjuvantPAM50TrastuzumabThe dual small molecule tyrosine kinase inhibitor lapatinib blocks both human epidermal ...
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and po... A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-...
sult—negative(0,1 )versuspositive(2 ,3 ).Thisinter-laboratorycomparisonsurveyincluded102laboratoriesin2004and141laboratoriesin2005.Results.—Ofthe160casesinbothsurveys,111(69%)achieved90%consensus(graded).All43gradedcoresscoredasIHC-positivewerefluorescenceinsituhybridiza-tion-positive,whereasallbut3of...
Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 t...
et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel...
[10] Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the Treatment of Breast Cancer. BioDrugs. 2016 Apr;30(2):75-86. [12] Bartsch R. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. Memo. 2021;14(3):247-251. ...
[3]Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. ...
[3]Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. ...
In breast cancer, HER3-DXd has shown promising activity across all subtypes, including hormone receptor-positive/HER2-negative (HR+/HER2-) disease. In a phase 1-2 clinical trial, HER3-DXd monotherapy was tested in 113 patients with heavily pre-treated HER3-expressing HR+/HER2- metastatic bre...
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for respo...